Clinical Trial Results

Shanghai – September 20, 2026 -- Abbisko Therapeutics Co., Ltd. (HKEX: 02256.HK) reported that its oral FGFR2/3 inhibitor lavengratinib achieved a mean increase of 2.4 cm/year in annualized height velocity among children with achondroplasia in the lowest-dose cohort of a Phase II trial, with a 100% responder rate.

Seven children in the first dose cohort completed six months of treatment with no serious adverse events

All seven participants aged 6 to 12 in cohort 1 of the ABSK061-202 study received lavengratinib at 0.064 mg/kg once daily for 27 weeks. Responders were defined as achieving at least a 25% improvement in annualized height velocity from baseline, a threshold every participant in the cohort met.

Atlanta and Los Angeles – September 20, 2026 -- StimCardio Medical reported that patients treated with non-invasive median nerve stimulation (MNS) after atrial fibrillation (AF) ablation showed 90.0% freedom from atrial arrhythmias at six months, compared with 80.8% for those receiving sham treatment, though the difference did not reach statistical significance. The randomized, double-blind, sham-controlled NeuroPulse pilot study was presented as late-breaking clinical science at HRX Live 2026 and simultaneously published in the peer-reviewed journal Heart Rhythm.

Post-blanking analysis finds statistically significant drop in arrhythmia events

In a sensitivity analysis conducted after the 60-day blanking period, patients receiving MNS recorded 12 recurrent atrial arrhythmia events versus 28 in the sham group, a statistically significant reduction (p=0.025). No MNS- or device-related serious adverse events were reported across the trial.

Seoul – September 16, 2026 -- Risvutatug rezetecan (Ris-Rez), a B7-H3-directed antibody-drug conjugate, reduced the risk of death by 54% compared with topotecan in patients with relapsed small-cell lung cancer, according to Phase III ARTEMIS-008 trial results presented at the IASLC 2026 World Conference on Lung Cancer.

Ris-Rez extends median overall survival to 18.5 months versus 10.3 months for topotecan

The multicenter, open-label trial (NCT06498479) randomized 461 patients in China 1:1 to receive Ris-Rez at 8.0 mg/kg every three weeks or topotecan at 1.2 mg/m2 on days 1 through 5 every three weeks. More than 80% of enrolled patients had previously received PD-(L)1 inhibitors. At the June 6, 2026 data cutoff, after a median follow-up of 12.2 months, the hazard ratio for death favored Ris-Rez at 0.46 (95% CI, 0.35–0.62; P0.0001), with the survival benefit consistent across relevant subgroups.

Seoul – September 12, 2026 -- SystImmune, Inc. announced that new global Phase 1 data support 2.5 mg/kg D1D8 Q3W as the recommended Phase 3 dose for iza-bren (izalontamab brengitecan), a bispecific EGFRxHER3 antibody drug conjugate, in previously treated EGFR-mutated metastatic non-small cell lung cancer (NSCLC).

Randomized Phase 1 cohort confirms higher efficacy at the 2.5 mg/kg dose level

The abstract, presented in an oral session at the IASLC 2026 World Conference on Lung Cancer (WCLC) in Seoul, South Korea, evaluated iza-bren across three dose levels in a randomized dose-expansion cohort. Patients enrolled had EGFR-mutated metastatic NSCLC and had previously received a third-generation EGFR inhibitor. Results showed promising antitumor activity with a manageable safety profile, with the highest efficacy observed at the 2.5 mg/kg dose.

Barcelona, Spain – September 15, 2026 -- Altesa BioSciences reported that its investigational oral antiviral vapendavir significantly reduced two key inflammatory biomarkers, IP-10/CXCL10 and GM-CSF, in COPD patients experimentally infected with rhinovirus, according to data presented at the European Respiratory Society (ERS) International Congress 2026.

Vapendavir lowers airway inflammation markers in Phase 2a challenge study

Nasal lavage samples from COPD patients treated with vapendavir showed significantly lower levels of IP-10/CXCL10 and GM-CSF compared to placebo over the course of rhinovirus infection. Two additional biomarkers, IFN-α2a and IFN-λ1/IL-29, trended lower with treatment but did not reach statistical significance.

SHERIDAN, WYOMING -- July 07, 2026 -- Roche announced positive results from the phase III Krascendo 1 study, showing that its investigational KRAS G12C inhibitor divarasib outperformed the approved first-generation inhibitors sotorasib and adagrasib in patients with previously treated KRAS G12C non-small cell lung cancer. The study met both its primary and key secondary endpoints, with divarasib delivering statistically significant improvements in progression-free survival and overall survival. Roche plans to submit the data to health authorities and present full results at an upcoming medical meeting. The company positions the results as evidence that divarasib could become a new treatment standard for this genetically defined subgroup of lung cancer patients.